KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Weighted Average) (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Shares Outstanding (Weighted Average) readings, the most recent being $1.2 billion for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.58% to $1.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 billion, a 1.58% increase, with the full-year FY2025 number at $1.1 billion, up 1.24% from a year prior.
  • Shares Outstanding (Weighted Average) hit $1.2 billion in Q1 2026 for Teva Pharmaceutical Industries, up from $1.1 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.2 billion in Q1 2026 to a low of $1.1 billion in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $1.1 billion (2024), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 0.54% in 2022 and later increased 1.58% in 2026.
  • Teva Pharmaceutical Industries' Shares Outstanding (Weighted Average) stood at $1.1 billion in 2022, then increased by 0.81% to $1.1 billion in 2023, then rose by 1.07% to $1.1 billion in 2024, then grew by 1.24% to $1.1 billion in 2025, then rose by 0.96% to $1.2 billion in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025) per Business Quant data.